Analysis Of The Effectiveness Of LMWH Compared To UFH In COVID-19 Patients With Coagulation Disorders At Pasar Minggu Regional General Hospital

Edwina Dharmawati; Yusi Anggriani; Muhammad Reza

Authors

Edwina Dharmawati Program Studi Magister Ilmu Kefarmasian, Universitas Pancasila
Yusi Anggriani Fakultas Farmasi, Universitas Pancasila
Muhammad Reza RSUD Pasar Minggu, Jakarta Selatan

Keywords:

Effectiveness, LMWH, UFH, Covid-19

Abstract

Background: COVID-19 disease causes multiorgan damage and impacts the cardiovascular system. The Increase in death cases occurs due to coagulation disorders characterized by increased d-dimer parameters, bleeding, thrombocytopenia, and thrombosis. Objective: To analyze the effectiveness of the use of LMWH anticoagulants compared to UFH in COVID-19 patients with coagulation disorders in hospital. Methods: Observational retrospective data collected1with cross sectional design. Methods of collecting data on COVID-19 inpatients in the January-December 2021 period based on moderate, severe, and critical severity of the disease. The data used is medical record data and analysis using chi square. Results: The sample consisted of 6362patients who met the inclusion criteria with the largest difference in decrease D-dimer values in critical severity for LMWH (4.8 ug/ml) and UFH (4.0 ug/ml). Wilcoxon test analysis *showed that there was a significant difference between the use of LMWH and UFH based on the decrease in D-dimer values.

Downloads

Download data is not yet available.

References

Chandra, A. et al. (2022) ‘Anticoagulation in COVID-19: current concepts and controversies’, Postgraduate Medical Journal, 98(1159), pp. 395–402. Available at: https://doi.org/10.1136/postgradmedj-2021-139923.

Cheng, A. et al. (2020) ‘Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID- 19 . The COVID-19 resource centre is hosted on Elsevier Connect , the company ’ s public news and information ’, (January).

Choirunnisa.Hekla (2021) ‘Hubungan Hipertensi dengan Mortalitas Pasien Covid-19 di Tangerang Selatan’, Jurnal Epidemiologi Kesehatan Indonesia, 5(2). Available at: https://doi.org/10.7454/epidkes.v5i2.5265.

Elviani, R. et al. (2021) ‘Gambaran Usia Pada Kejadian Covid-19’, JAMBI MEDICAL JOURNAL ‘Jurnal Kedokteran dan Kesehatan’, 9(1), pp. 204–209. Available at: https://doi.org/10.22437/jmj.v9i1.11263.

Fahmia, R. et al. (2022) ‘Lama Rawat Inap Pasien Terkonfirmasi COVID-19 di Rumah Sakit Universitas Indonesia dan Faktor yang Mempengaruhinya.’, Jurnal Epidemiologi Kesehatan Indonesia, 6(1), pp. 1–12. Available at: https://doi.org/10.7454/epidkes.v6i1.5004.

Gonzalez-Porras, J.R. et al. (2020) ‘Low Molecular Weight Heparin in Adults Inpatient COVID-19’, SSRN Electronic Journal [Preprint]. Available at: https://doi.org/10.2139/ssrn.3586665.

Gunawan, A. et al. (2020) ‘Pengaruh Komorbid Hipertensi Terhadapseveritas Pasien Coronavirus Disease 2019’, Jurnal Implementa HUSADA, 1(2), pp. 136–151.

He, P. et al. (2018) ‘Comparison of enoxaparin and unfractionated heparin in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention: A systematic review and meta-analysis’, Journal of Thoracic Disease, 10(6), pp. 3308–3318. Available at: https://doi.org/10.21037/jtd.2018.05.113.

Khan, I.H. et al. (2020) ‘The need to manage the risk of thromboembolism in COVID-19 patients’, Journal of Vascular Surgery, 72(3), pp. 799–804. Available at: https://doi.org/10.1016/j.jvs.2020.05.015.

Lodigiani, C. et al. (2020) ‘Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan , Italy’, Thrombosis Research, 191(April), pp. 9–14. Available at: https://doi.org/10.1016/j.thromres.2020.04.024.

Martel, N. et al. (2005) ‘Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: A meta-analysis’, Blood, 106(8), pp. 2710–2715. Available at: https://doi.org/10.1182/blood-2005-04-1546.

Mulyadi,*, B. et al. (2018) ‘Trombositopenia Pada Pengobatan Dengan Heparin’, Indonesian Journal of Clinical Pathology and Medical Laboratory, 13(3), p. 114. Available at: https://doi.org/10.24293/ijcpml.v13i3.913.

Nasiri, M.J. et al. (2020) ‘COVID-19 Clinical Characteristics, and Sex-Specific Risk of Mortality: Systematic Review and Meta-Analysis’, Frontiers in Medicine, 7(July), pp. 1–10. Available at: https://doi.org/10.3389/fmed.2020.00459.

Putra, M.M.A. et al. (2022) ‘Risiko Perdarahan Spontan pada Pasien COVID-19 dengan Terapi Antikoagulan - Serial Kasus’, Majalah Anestesia & Critical Care, 40(2), pp. 119–130. Available at: https://doi.org/10.55497/majanestcricar.v40i2.246.

Rusdiana, T. et al. (2020) ‘Perkembangan Terkini Terapi Antikoagulan Pada Pasien Covid-19 Bergejala Berat’, Jurnal Sains Farmasi & Klinis, 7(3), p. 244. Available at: https://doi.org/10.25077/jsfk.7.3.244-250.2020.

Sakka, M. et al. (2020) ‘Association between D-Dimer levels and mortality in patients with coronavirus disease 2019 ( COVID-19 ): a systematic review and pooled analysis’, JMV-Journal de Médecine Vasculaire, 2019, pp. 1–7. Available at: https://doi.org/10.1016/j.jdmv.2020.05.003.

Setiadi, F. et al. (2021) ‘Pengaruh Penggunaan Antikoagulan Terhadap Penurunan Nilai D-Dimer pada Pasien COVID-19 Effect of Anticoagulant Use on Reducing D-Dimer in COVID-19 Patients’, 8(2), pp. 30–40.

Sunggoro, A.J. et al. (2020) ‘Trombosis pada corona virus disease (COVID-19)’, Jurnal Kedokteran Syiah Kuala, 20(3), pp. 191–198. Available at: https://doi.org/10.24815/jks.v20i3.18689.

Tang, N., Li, D., et al. (2020) ‘Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia’, Journal of Thrombosis and Haemostasis, 18(4), pp. 844–847. Available at: https://doi.org/10.1111/jth.14768.

Tang, N., Bai, H., et al. (2020) ‘Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy’, Journal of Thrombosis and Haemostasis, 18(5), pp. 1094–1099. Available at: https://doi.org/10.1111/jth.14817.

Thachil, J. et al. (2020) ‘ISTH interim guidance on recognition and management of coagulopathy in COVID-19’, Journal of Thrombosis and Haemostasis, 18(5), pp. 1023–1026. Available at: https://doi.org/10.1111/jth.14810.

Volteas, P. et al. (2021) ‘Low-molecular-weight heparin compared with unfractionated heparin in critically ill COVID-19 patients’, Journal of Vascular Surgery: Venous and Lymphatic Disorders, 10(5), pp. 1128–1136. Available at: https://doi.org/10.1016/j.jvsv.2022.04.019.

Wu, C. et al. (2020) ‘Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China’, JAMA Internal Medicine, 180(7), pp. 934–943. Available at: https://doi.org/10.1001/jamainternmed.2020.0994.

Zhang, P. et al. (2020) ‘Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality among Patients with Hypertension Hospitalized with COVID-19’, Circulation Research, 126(12), pp. 1671–1681. Available at: https://doi.org/10.1161/CIRCRESAHA.120.317134.